Pharma Penny Stock Under Rs 30: Company Incorporates Subsidiaries in Canada & USA and Approves Fund Raising of Rs 1,500 Crore
Pharma Penny Stock Under Rs 30: Company Incorporates Subsidiaries in Canada & USA and Approves Fund Raising of Rs 1,500 Crore
The stock gave multibagger returns of 277 per cent from its 52-week low of Rs 7.71 per share.
The stock gave multibagger returns of 277 per cent from its 52-week low of Rs 7.71 per share.
Pharma penny stock under Rs 50 in focus as company inaugurates its state-of-the-art R&D center in Hyderabad
From Rs 34.51 per share (52-week low) to Rs 56.15 per share, the stock is up by 55.3 per cent.
From Rs 34.51 per share (52-week low) to Rs 56.15 per share, the stock is up by 55.3 per cent.
Pharma Penny Stock Under Rs 30: Board to Meet on June 19 to Consider, Evaluate and Approve Proposal of Raising Further Funds
The stock gave multibagger returns of 292 per cent from its 52-week low of Rs 7.35 per share.
The stock gave multibagger returns of 292 per cent from its 52-week low of Rs 7.35 per share.
Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why!
The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share.
The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share.
Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration
The company has a market cap of Rs 287 crore and the stock is up by 6 per cent from its 52-week low of Rs 49.20 per share.
The shares of the company have a PE of 12x whereas the industry PE is 36x.
From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India
The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.
The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.
Pharma Penny Stock Under Rs 50 Approves FY25 Audited Results; Recommended Rs 0.10 Dividend & Approves Rs 37.22 Cr Acquisition in Trimax Bio Sciences
From Rs 34.51 per share (52-week low) to Rs 53.59 per share, the stock is up by 55.3 per cent.
From Rs 34.51 per share (52-week low) to Rs 53.59 per share, the stock is up by 55.3 per cent.
Low PE pharma penny stock below Rs 60 jumps 14.50 per cent after reporting turnaround net profit of Rs 25 crore in FY25
The company has a market cap of over Rs 300 crore and the stock is up by 16.34 per cent from its 52-week low of Rs 49.20 per share.
The company has a market cap of over Rs 300 crore and the stock is up by 16.34 per cent from its 52-week low of Rs 49.20 per share.
40 Per Cent Returns from 52-Week Low; Board Announce 1:1 Bonus Shares and 30 Per Cent Dividend
The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share.
The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share.
2:1 Stock Split: Gujarat-Based Penny Stock Under Rs 2 Hit Upper Circuits as PAT Jumps 14,940 Per Cent in FY25
The stock is trading at 0.65 times its book value and the stock is up by 36 per cent from its 52-week low of Rs 1.04 per share.
The stock is trading at 0.65 times its book value and the stock is up by 36 per cent from its 52-week low of Rs 1.04 per share.
47 Per Cent Returns from 52-Week Low; Board Likely to Announce Bonus Shares and Dividend
The stock is up by 47 per cent from its 52-week low of Rs 148.05 per share.
The company has a market cap of over Rs 1,000 crore and has delivered good profit growth of 19 per cent CAGR over the last 5 years with a healthy dividend payout of 26 per cent.
CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA
The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.